$15.78 $0.59 (3.9%)

08:00 PM EST on 02/14/20

TG Therapeutics, Inc. (NASDAQ:TGTX)

CAPS Rating: 3 out of 5

Current Price $15.78 Mkt Cap $1.5B
Open $0.00 P/E Ratio 0.00
Prev. Close $15.78 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 1,895,932
52-Wk Range $10.48 - $16.20 Avg. Daily Vol. 2,015,215

Caps

How do you think NASDAQ:TGTX will perform against the market?

Add Stock to CAPS Watchlist

All Players

59 Outperform
3 Underperform
 

All-Star Players

14 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:TGTX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.55)
Submitted February 13, 2015

TG Therapeutics has been a popular topic on biotwitter for a couple of years, but I never had the time to put the stock into my database so I wasn't around for the monster move from 5 to 18 last year. Would I have taken the plunge and started a real… More

OklaBoston (< 20)
Submitted August 25, 2015

Only a matter of time before this loses at least 1 Star. AT LEAST 1!

NASDAQ:TGTX VS S&P 500 (SPY)

Fools bullish on NASDAQ:TGTX are also bullish on:

Fools bearish on NASDAQ:TGTX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about TGTX.

Recs

0
Member Avatar TurksFan (43.58) Submitted: 4/7/2018 8:43:26 AM : Outperform Start Price: $13.20 NASDAQ:TGTX Score: -9.62

Starting my research into biotechs

Recs

0
Member Avatar TMFEBCapital (91.82) Submitted: 4/30/2017 1:16:33 PM : Outperform Start Price: $11.00 NASDAQ:TGTX Score: +2.01

While it's anyone's guess if the FDA will require a second trial to confirm TG-1101s efficacy alongside Imbruvica in CLL before approving it, upcoming presentations in June at ASCO could help boost this company's shares over the coming month. After the conference, investors should have more info to digest on safety that could inform the chances of this drug getting across the regulatory finishline.

Recs

0
Member Avatar biotechf (98.27) Submitted: 3/28/2015 5:06:22 PM : Outperform Start Price: $16.02 NASDAQ:TGTX Score: -64.61

The company's cancer drug is in trials with Pharmacyclics drug. Pharmacyclics is set to be acquired by Abbvie and thus TGTX may be another acquisition target for big pharma. A major medical meeting is coming soon and I expect TGTX's stock to run up in anticipation of this event.

Leaderboard

Find the members with the highest scoring picks in TGTX.

Score Leader

thiscoloradokid

thiscoloradokid (< 20) Score: +272.97

TGTX has been a flat line on a weekly chart for over 2 years. It's now attracting significant accumulation. A very low relative price, long base, and increasing volume is very attractive.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
thiscoloradokid < 20 11/14/2013 Outperform 3M $3.42 +361.40% +88.43% +272.97 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Baseballmom1123 < 20 11/20/2013 Outperform 3Y $3.49 +352.15% +89.18% +262.97 0 Comment
allforone 35.98 12/31/2018 Outperform 3Y $4.10 +284.88% +36.01% +248.87 0 Comment
drugtrader 92.29 10/8/2018 Outperform 5Y $5.35 +194.95% +17.61% +177.34 0 Comment
DrDoofenshmirtz 99.82 9/27/2018 Outperform 5Y $5.53 +185.61% +15.85% +169.76 0 Comment
efarev 98.08 10/1/2018 Outperform 5Y $5.60 +181.79% +15.57% +166.21 0 Comment
simplemts < 20 10/12/2018 Outperform 5Y $5.64 +179.79% +21.98% +157.81 0 Comment
StockElections 28.41 5/15/2014 Outperform 5Y $4.69 +236.46% +80.68% +155.79 0 Comment
TerryFool 22.10 4/15/2014 Outperform 5Y $5.00 +215.60% +85.37% +130.23 1 Comment
TerryHoodSr 65.62 4/15/2014 Outperform 5Y $5.26 +200.00% +84.36% +115.64 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for TGTX.